Advaxis enters $540mm immunotherapy deal with Amgen
Advaxis Inc. licensed Amgen Inc. exclusive worldwide rights to develop and sell its preclinical cancer immunotherapy ADXSNEO, the first project to arise from Advaxis' new MINE (MyImmunotherapy Neo-Epitopes) program for customizable cancer treatments.
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.